Notably, the baseline assessment ruled out established factors for hyperparathyroidism in this patient, including chronic kidney disease (16), prior exposure to PTH-like agents (17), and denosumab administration (18), which strengthens the evidence for an association between pembrolizumab and the development of hyperparathyroidism. Here, PTH is linked to hyperparathyroidism.